Neonc Technologies Holdings, Inc. (NTHI) Stock

Neonc Technologies Holdings, Inc. (NTHI) is a Healthcare stock trading at $4.68 (as of 2026-08-21), with a market capitalization of $121.38M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Neonc Technologies Holdings, Inc. develops molecular technologies aimed at improving targeted delivery of therapeutic payloads for central nervous system diseases. Its pipeline includes NEO100, in Phase 2a clinical trials for glioblastoma, and NEO212, a covalently conjugated molecule combining temozolomide with perillyl alcohol that has completed preclinical testing.

Understand Neonc Technologies Holdings, Inc.: how it makes money

Neonc Technologies develops novel molecular technology for enhanced targeted delivery of therapies for central nervous system diseases, with lead programs NEO100 (Phase 2a) and NEO212 (completed preclinical testing). Its value depends on progressing clinical and preclinical development toward later commercialization or partnership opportunities.

The profit model is driven by whether its targeted-delivery drug candidates (NEO100 in Phase 2a, NEO212 in preclinical) generate supportive clinical readouts that enable the programs to advance and attract further development capital and commercial interest.

Business quality (Solid): Early-stage therapeutic development (incorporated in 2023), with focus on clinical efficacy readouts for NEO100 and preclinical progress for NEO212, while current period financials show zero revenue listed and a large negative operating margin.

Bull case

  • NEO100 is in Phase 2a clinical trials: The company’s lead product NEO100 is in Phase 2a for glioblastoma.
  • Reported clinical metrics for NEO100: Operational indicators provided include a Radiographic Remission Rate of 24% and a Progression-Free Survival at Six Months of 44%.
  • NEO212 has completed preclinical testing: NEO212 is described as completed preclinical testing after combining temozolomide with perillyl alcohol.

Bear case

  • Negative operating performance in the latest period: For the period 2025-09-30, operating_margin_pct is reported as -17341.0.
  • Program and cohort size constraints: The NEO100 clinical cohort size is provided as 25, which can limit how confidently early results predict broader outcomes.
  • Development-stage uncertainty: NEO100 remains in Phase 2a and NEO212 is in the preclinical stage, so future clinical success is not guaranteed.
Valuation — source: SEC EDGAR (first-party)
Price$4.68
Market Cap$121.38M
Price / Sales1011.77
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$39990.00
Net Margin-155404.4%
Revenue Growth (YoY)-51.8%
EPS Growth (YoY)363.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-128.39 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCinctive Capital Management LP ($9.99M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOAmir Farrokh Heshmatpour
Employees8
CountryUS
IPO Date2025-03-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Spruce Biosciences, Inc. (SPRB)
  • TuHURA Biosciences, Inc. (HURA)
  • Anixa Biosciences, Inc. (ANIX)
  • Genelux Corporation (GNLX)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Cumberland Pharmaceuticals Inc. (CPIX)
  • Coya Therapeutics, Inc. (COYA)
  • Rafael Holdings, Inc. (RFL)
NTHI earnings history · NTHI institutional & insider holders · NTHI KPIs & operating metrics · NTHI financials · NTHI investor presentations & press releases · NTHI SEC filings · NTHI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.